Article

Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction

2023-03-06

Abstract excerpt

Macrophage immune checkpoint inhibitors, such as anti-CD47 antibodies, show promise in clinical trials for solid and hematologic malignancies. However, the best strategies to use these therapies remain unknown and ongoing studies suggest they may be most effective when used in combination with other anticancer agents. Here, we developed a novel screening platform to identify drugs that render lung cancer cells mor...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a22a7205-2856-5c12-9340-dd89866b1ca2
DOI: 10.1101/2023.03.03.531059

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destructionDOI 10.1101/2023.03.03.531059Read

Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction.Semantic proximity Read

EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47.Semantic proximity Read

CD47 predominates over CD24 as a macrophage immune checkpoint in cancerSemantic proximity Read

Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.Semantic proximity Read

Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα AxisSemantic proximity Read

Macrophages, Inflammation, and Lung Cancer.Semantic proximity Read

DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunitySemantic proximity Read

Organoid modeling of tumor-associated macrophages reveals phagocytosis checkpoint blockade-induced conversion to an immunosuppressive SPP1+ phenotypeSemantic proximity Read

Recent Advances of Tumor Therapy Based on the CD47-SIRPα AxisSemantic proximity Read

CD47 promotes mitogen-activated protein kinase and epithelial-to-mesenchymal transition molecular programs to drive prometastatic phenotypes in non-small cell lung cancer.Semantic proximity Read

An immune-stimulating antibody conjugate spatiotemporally targeting CD47 and TLR9 elicits macrophage-dependent tumor clearance and durable anti-cancer adaptive immunitySemantic proximity Read

Pharmacological rescue of tumor intrinsic STING expression and immune response in LKB1-mutant lung cancer via the IAP-JAK regulatory axisSemantic proximity Read